

FRANCO LA POSTA, CPA

September 29, 2021

British Columbia Securities Commission
Alberta Securities Commission
Saskatchewan Financial Services Commission
Ontario Securities Commission
TSX Venture Exchange Inc.

Dear Sirs/Mesdames,

I refer to the non-offering prospectus dated September 29, 2021 of BuzBuz Capital Corp. related to the proposed qualifying transaction between BuzBuz Capital Corp and Inolife R&D Inc.

I consent to be named and to the use in the above-mentioned non-offering prospectus, of my report dated August 19, 2021, to the shareholder of European Pharma Group B.V., a subsidiary of Inolife R&D Inc., on the following financial statements:

- Consolidated statements of financial position as at June 4, 2020 and December 31, 2019; and,
- Consolidated statements of loss and comprehensive loss, changes in shareholders' equity and cash flows and the notes to the financial statements for each of the periods ended June 4, 2020 and December 31, 2019.

I report that I have read the non-offering prospectus and all information therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which I have reported or that are within my knowledge as a result of my audit of such financial statements. I have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Signed: "Franco La Posta"

Franco La Posta

Montreal, Quebec
September 29, 2021

¹ CPA Auditor, CA, public accountancy permit No. A106908